Malash A E, Al-Esnawy A A, Ereiba Khairy T, Bakr Ahmed M, Abdraboh A S
Physics Department, Faculty of Science, Al-Azhar University, Nasr City, Cairo, 11884, Egypt.
Spectroscopy Department, Physics Research Division, National Research Centre, 33 El Bohouth St., Dokki, Giza, 12622, Egypt.
Sci Rep. 2025 Jan 17;15(1):2231. doi: 10.1038/s41598-025-85702-y.
This study aims to synthesize a new localized drug delivery system of bioglass, polyvinyl alcohol (PVA), cellulose (CNC), and sodium alginate (SA) beads as a carrier for methotrexate (MTX) drugs for the treatment of osteosarcoma. Methotrexate /Bioglass-loaded Polyvinyl/Cellulose/Sodium alginate biocomposite beads were prepared via the dropwise method with different concentrations of (65%SiO-30%CaO- 5%PO) bioglass. Samples were named B0, S0, S1, S2, and S3, respectively. Calcium chloride (CaCl) was used as a cross-linking agent. The obtained biocomposite beads were investigated by different techniques FTIR, XRD, SEM, etc. The bioactivity of MTX/BG-loaded PVA-CNC-SA biocomposite beads was tested by immersion in simulated body fluid (SBF). The profile release of methotrexate was investigated with UV-vis spectroscopy for 30 days. A cytotoxicity study of the methotrexate was performed by a human osteosarcoma (MG-63) cell line. Results indicated that the formation of a hydroxyapatite layer on the bead's surface confirmed its biological activity. Bioactivity was directly proportional to the BG content. All samples of B1, S0, S1, S2, and S3 exhibited significant maximum release up to 6 days and were controlled gradually. Cytotoxicity results of biocomposite beads showed that high cell death was detected on the MG-63 cells, with (IC-50 ± SD) of S3 (116.16 ± 1.57) compared with B1 (306.99 ± 2.72) and S1 (204.74 ± 4.55) due to the high release of MTX, which was confirmed by the results of the drug release profile. Results prove that the prepared biocomposite beads can be used as bioactive, drug delivery systems, and anticancer materials.
本研究旨在合成一种新型的生物玻璃、聚乙烯醇（PVA）、纤维素（CNC）和海藻酸钠（SA）珠粒的局部药物递送系统，作为甲氨蝶呤（MTX）药物治疗骨肉瘤的载体。通过滴加法制备了负载甲氨蝶呤/生物玻璃的聚乙烯醇/纤维素/海藻酸钠生物复合珠粒，其中生物玻璃的浓度不同（65%SiO-30%CaO-5%PO）。样品分别命名为B0、S0、S1、S2和S3。氯化钙（CaCl）用作交联剂。通过傅里叶变换红外光谱（FTIR）、X射线衍射（XRD）、扫描电子显微镜（SEM）等不同技术对所得生物复合珠粒进行了研究。通过将负载MTX/BG的PVA-CNC-SA生物复合珠粒浸入模拟体液（SBF）中来测试其生物活性。用紫外可见光谱法研究了甲氨蝶呤30天的释放曲线。通过人骨肉瘤（MG-63）细胞系对甲氨蝶呤进行了细胞毒性研究。结果表明，珠粒表面形成羟基磷灰石层证实了其生物活性。生物活性与BG含量成正比。B1、S0、S1、S2和S3的所有样品在长达6天的时间内均表现出显著的最大释放，并逐渐得到控制。生物复合珠粒的细胞毒性结果表明，与B1（306.99±2.72）和S1（204.74±4.55）相比，S3（116.16±1.57）对MG-63细胞检测到高细胞死亡，这是由于MTX的高释放所致，药物释放曲线的结果证实了这一点。结果证明，所制备的生物复合珠粒可作为生物活性药物递送系统和抗癌材料。
